FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313532444> ?p ?o ?g. }

• W4313532444 abstract "<h3>Background</h3> Despite standard therapy (ST) for LN, only 20–40% of pts achieve Complete Renal Response (CRR) at 0.5–1 year and 20–25% relapse in 3–5 years. Achieving CRR is often more difficult in relapsed patients than in <i>de novo</i> patients. The aim of this study was to assess effects of BEL on renal outcomes in relapsed and newly diagnosed pts with LN. <h3>Methods</h3> A post hoc analysis of the Phase 3, randomized, double-blind, 104-week BLISS-LN study (GSK BEL114054; NCT01639339) was performed. Pts with active LN received monthly intravenous (IV) BEL 10 mg/kg or placebo (PBO) + ST. Randomization was stratified by induction regimen: high dose corticosteroids (HDCS) + cyclophosphamide (CYC), followed by azathioprine + low-dose corticosteroids (LDCS), or HDCS + mycophenolate mofetil (MMF), followed by MMF + LDCS. We assessed Primary Efficacy Renal Response (PERR; uPCR ≤0.7; eGFR no more than 20% below pre-flare value or ≥60 ml/min/1.73m²; no rescue therapy) and CRR (uPCR <0.5; eGFR no more than 10% below pre-flare value or ≥90 ml/min/1.73m²; no rescue therapy) at Week 104 and time to renal-related event or death in relapsed vs newly diagnosed pts. <h3>Results</h3> Of 446 pts included in this analysis, 150 had relapse of LN and 296 were newly diagnosed. Positive effects of BEL vs PBO on PERR and CRR were noted in both subgroups but were numerically greater in relapsed vs newly diagnosed pts (table 1). BEL-treated pts had a lower risk at any time of experiencing a renal-related event or death vs PBO in both subgroups (table 1). <h3>Conclusions</h3> These data suggest BEL improved PERR and CRR rates more potently in relapsed pts, in which PERR and CRR were substantially less frequent compared with newly diagnosed LN. <h3>Acknowledgement</h3> Abstract¹ reprinted from ASN Kidney Week, October 25–November 7, 2021. <h3>Reference</h3> Hans-Joachim Anders, Brad Rovin, Ming-Hui Zhao, Ana Malvar, Keiju Hiromura, Angela R Jones- Leone, Tania Gonzalez Rivera, Jennifer Gilbride, Anu Madan, Yulia Green, David Roth. Effects of Belimumab (BEL) on Renal Outcomes in Patients With Relapsed and Newly Diagnosed Active Lupus Nephritis (LN). <i>J Am Soc Nephrol.</i> 2021;<b>32</b>:48. <h3>Funding</h3> GSK. Editorial assistance with encore abstract development was provided by Paragon, UK (funded by GSK). <h3>Disclosures</h3> <b>HJA</b> has received consultancy fees from GSK, Novartis, AstraZeneca, Janssen, Kezar, Bayer, PreviPharma, Idorsia and Boehringer, and honoraria from GSK, Novartis, AstraZeneca, Janssen, Kezar, Bayer, PreviPharma, Idorsia, Boehringer, Lilly; is a Scientific Advisor/Membership for ERA-EDTA and an Associated editor at JASN and NDT. <b>BHR</b> has received consultancy fees from GSK. <b>MHZ</b> has received consultancy fees from GSK, AstraZeneca and Roche. <b>A Malvar</b> has received consultancy fees from GSK and Roche. <b>KH</b> has received consultancy fees from GSK. <b>AJL</b>, <b>TGR</b>, <b>JG</b>, <b>A Madan</b>, <b>YG</b> and <b>DAR</b> are employees of GSK and hold stocks and shares in the company." @default.
• W4313532444 created "2023-01-06" @default.
• W4313532444 creator A5008236609 @default.
• W4313532444 creator A5009036785 @default.
• W4313532444 creator A5010478903 @default.
• W4313532444 creator A5022937823 @default.
• W4313532444 creator A5023279987 @default.
• W4313532444 creator A5030585977 @default.
• W4313532444 creator A5034488510 @default.
• W4313532444 creator A5038025628 @default.
• W4313532444 creator A5042356850 @default.
• W4313532444 creator A5067360216 @default.
• W4313532444 creator A5083359321 @default.
• W4313532444 date "2022-12-01" @default.
• W4313532444 modified "2023-10-18" @default.
• W4313532444 title "1104 Effects of Belimumab (BEL) on Renal Outcomes in Patients (pts) With Relapsed and Newly Diagnosed Active Lupus Nephritis (LN)" @default.
• W4313532444 doi "https://doi.org/10.1136/lupus-2022-lupus21century.69" @default.
• W4313532444 hasPublicationYear "2022" @default.
• W4313532444 type Work @default.
• W4313532444 citedByCount "0" @default.
• W4313532444 crossrefType "proceedings-article" @default.
• W4313532444 hasAuthorship W4313532444A5008236609 @default.
• W4313532444 hasAuthorship W4313532444A5009036785 @default.
• W4313532444 hasAuthorship W4313532444A5010478903 @default.
• W4313532444 hasAuthorship W4313532444A5022937823 @default.
• W4313532444 hasAuthorship W4313532444A5023279987 @default.
• W4313532444 hasAuthorship W4313532444A5030585977 @default.
• W4313532444 hasAuthorship W4313532444A5034488510 @default.
• W4313532444 hasAuthorship W4313532444A5038025628 @default.
• W4313532444 hasAuthorship W4313532444A5042356850 @default.
• W4313532444 hasAuthorship W4313532444A5067360216 @default.
• W4313532444 hasAuthorship W4313532444A5083359321 @default.
• W4313532444 hasBestOaLocation W43135324441 @default.
• W4313532444 hasConcept C126322002 @default.
• W4313532444 hasConcept C126894567 @default.
• W4313532444 hasConcept C142724271 @default.
• W4313532444 hasConcept C159654299 @default.
• W4313532444 hasConcept C170286685 @default.
• W4313532444 hasConcept C203014093 @default.
• W4313532444 hasConcept C204787440 @default.
• W4313532444 hasConcept C27081682 @default.
• W4313532444 hasConcept C2776694085 @default.
• W4313532444 hasConcept C2776755627 @default.
• W4313532444 hasConcept C2776760755 @default.
• W4313532444 hasConcept C2778283404 @default.
• W4313532444 hasConcept C2778453870 @default.
• W4313532444 hasConcept C2779134260 @default.
• W4313532444 hasConcept C2779912601 @default.
• W4313532444 hasConcept C2781205201 @default.
• W4313532444 hasConcept C2781413609 @default.
• W4313532444 hasConcept C67761136 @default.
• W4313532444 hasConcept C71924100 @default.
• W4313532444 hasConcept C90924648 @default.
• W4313532444 hasConceptScore W4313532444C126322002 @default.
• W4313532444 hasConceptScore W4313532444C126894567 @default.
• W4313532444 hasConceptScore W4313532444C142724271 @default.
• W4313532444 hasConceptScore W4313532444C159654299 @default.
• W4313532444 hasConceptScore W4313532444C170286685 @default.
• W4313532444 hasConceptScore W4313532444C203014093 @default.
• W4313532444 hasConceptScore W4313532444C204787440 @default.
• W4313532444 hasConceptScore W4313532444C27081682 @default.
• W4313532444 hasConceptScore W4313532444C2776694085 @default.
• W4313532444 hasConceptScore W4313532444C2776755627 @default.
• W4313532444 hasConceptScore W4313532444C2776760755 @default.
• W4313532444 hasConceptScore W4313532444C2778283404 @default.
• W4313532444 hasConceptScore W4313532444C2778453870 @default.
• W4313532444 hasConceptScore W4313532444C2779134260 @default.
• W4313532444 hasConceptScore W4313532444C2779912601 @default.
• W4313532444 hasConceptScore W4313532444C2781205201 @default.
• W4313532444 hasConceptScore W4313532444C2781413609 @default.
• W4313532444 hasConceptScore W4313532444C67761136 @default.
• W4313532444 hasConceptScore W4313532444C71924100 @default.
• W4313532444 hasConceptScore W4313532444C90924648 @default.
• W4313532444 hasLocation W43135324441 @default.
• W4313532444 hasLocation W43135324442 @default.
• W4313532444 hasOpenAccess W4313532444 @default.
• W4313532444 hasPrimaryLocation W43135324441 @default.
• W4313532444 hasRelatedWork W1970488300 @default.
• W4313532444 hasRelatedWork W1978468861 @default.
• W4313532444 hasRelatedWork W1992216971 @default.
• W4313532444 hasRelatedWork W2031170418 @default.
• W4313532444 hasRelatedWork W2068124840 @default.
• W4313532444 hasRelatedWork W2124506873 @default.
• W4313532444 hasRelatedWork W2157460346 @default.
• W4313532444 hasRelatedWork W2436630400 @default.
• W4313532444 hasRelatedWork W2734754122 @default.
• W4313532444 hasRelatedWork W4413142 @default.
• W4313532444 isParatext "false" @default.
• W4313532444 isRetracted "false" @default.
• W4313532444 workType "article" @default.